)
)
)
Investing in the Future of Cardiometabolic and Longevity Therapies: Differentiating Pipelines
GLP-1 analogs have already rewritten treatment standards and changed patients’ expectations related to obesity. Evidence continues to build that such pathways can improve cardiometabolic health more broadly and treat seemingly unrelated disease areas. This points to new cellular and systemic approaches with implications for longevity R&D as well. This panel will discuss the connections between clinical evidence and the discovery work revealing new metabolic insights.